JUPITER NEUROSCIENCES, INC. Stock Price, News & Analysis

Jupiter Neurosciences (NASDAQ: JUNS) announced that its management team will present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference (NobleCon21) on December 2–3, 2025 in Boca Raton, Florida.

Management will be available for qualified one-on-one investor meetings during the event and investors can schedule meetings by contacting a NobleCon representative or investor relations via JUNS@redchip.com. NobleCon21 is described as a forum for emerging growth companies, investor access, presentations, and networking opportunities.

Jupiter Neurosciences (NASDAQ:JUNS) announced that the FDA cleared its IND to initiate a Phase 2a clinical trial of JOTROL in Parkinson’s disease on November 5, 2025. The clearance enables enrollment for an exploratory Phase 2a study focused on safety and tolerability with secondary PK/PD and biomarker endpoints, and the company expects to begin enrollment in early 2026. Preclinical MPTP-model data showed improved motor endpoints; the company reports its micellar delivery achieves >9-fold higher bioavailability versus traditional resveratrol. Jupiter continues collaboration with Zina Biopharmaceuticals for protocol design and site selection.

Jupiter Neurosciences (NASDAQ: JUNS) entered into financing agreements with an affiliate of Yorkville Advisors providing access to up to $20 million in capital to support its Phase 2 Parkinson’s trial for JOTROL™ and expansion of the Nugevia™ consumer product line. The financing includes a $6 million prepaid advance (initial $4 million funded on Oct 24, 2024) evidenced by convertible promissory notes with a $1.50 fixed conversion price, and a standby equity purchase agreement (SEPA) to sell up to $14 million of common stock over 24 months subject to an effective registration statement. Prepaid advances carry a 7% original issue discount, interest, and 12‑month maturity; SEPA share issuances may be at a 3.0% discount to market. Proceeds will be used for the Phase 2 trial, DTC marketing for Nugevia™, working capital, and general corporate purposes.

Jupiter Neurosciences (NASDAQ:JUNS) has appointed Jean Fallacara, a renowned entrepreneur and neuroscientist, as the third brand ambassador for their consumer longevity supplement line Nugevia™. Fallacara, recognized as one of the "Most Disruptive Entrepreneurs 2023," brings extensive experience in biohacking and biotechnology, including founding Z-Sciences, which was acquired by inTEST Corp in 2021.

Nugevia™ is built on JOTROL™, Jupiter's patented resveratrol-based micellar delivery platform with enhanced bioavailability. The product line includes three formulations: GLO, MND, and PWR, designed to support cellular resilience. This consumer initiative is part of Jupiter's dual-path strategy, targeting the longevity market projected to reach $8 trillion by 2030, while supporting their clinical development programs.

Jupiter Neurosciences (NASDAQ: JUNS) has launched its Nugevia™ e-commerce platform, marking its entry into the $8 trillion global longevity market. The company is now accepting pre-orders for three nutraceutical supplements: Nugevia™ GLO, PWR, and MND, with shipping starting Fall 2025.

The products leverage Jupiter's patented JOTROL™ resveratrol delivery platform, which demonstrated a nine-fold increase in bioavailability in Phase I trials. This launch represents a dual-path business strategy, combining CNS therapeutic development with consumer health products. The company has also secured Hall of Fame golfer Annika Sörenstam and NBA legend Chris Webber as brand ambassadors.

Jupiter Neurosciences (NASDAQ: JUNS) has announced NBA Hall of Famer Chris Webber as the second brand ambassador for their Nugevia™ longevity supplement line. The five-time NBA All-Star will promote the company's science-backed supplements built on the JOTROL™ platform, a patented resveratrol-based micellar delivery system.

The product line features three formulations - GLO, MND, and PWR - designed to enhance cellular resilience through synergistic ingredients optimized for absorption. This consumer initiative is part of Jupiter's dual-path strategy, targeting the $8 trillion longevity market by 2030 while supporting their clinical development programs and operational costs.

Jupiter Neurosciences (NASDAQ: JUNS) has launched Nugevia™ MND, a cognitive health supplement combining their proprietary JOTROL™ resveratrol technology with NovaSOL® Curcumin. The product targets the $8 trillion longevity and wellness markets and will be available Fall 2025.

The supplement aims to enhance cognitive performance and neuroprotective health through multiple pathways, including reducing oxidative stress and inflammation. CEO Christer Rosén emphasized the personal significance of the product, citing family experiences with Alzheimer's and Parkinson's diseases.

Nugevia MND represents a strategic move to generate high-margin revenue while complementing Jupiter's pharmaceutical pipeline. The company plans to leverage consumer usage data alongside biomarker data from their upcoming Phase II Parkinson's disease trial to inform future cognitive health programs.

Jupiter Neurosciences (NASDAQ: JUNS) has highlighted the significant advantages of its proprietary JOTROL™ platform over traditional resveratrol formulations. The company's breakthrough demonstrates 9x higher bioavailability compared to conventional resveratrol, without gastrointestinal side effects at therapeutic doses.

JOTROL™ has shown ability to cross the blood-brain barrier and is advancing to Phase IIa trials for Parkinson's Disease. The platform's intellectual property is secured through 2036 across major markets. Jupiter plans to launch its Nugevia™ consumer product line in Q3 2025, featuring formulations for cognitive health, mitochondrial energy, and skin vitality.

Jupiter Neurosciences (NASDAQ: JUNS), a clinical-stage pharmaceutical company developing JOTROL™, has successfully regained compliance with Nasdaq's minimum bid price requirement. The company's stock maintained an average closing price of at least $1.00 for 13 consecutive trading days from June 18 to July 8, 2025.

The compliance confirmation was received on July 9, 2025, from Nasdaq's Listing Qualifications Department, effectively resolving the previous listing concern. Jupiter's shares are now fully compliant with Rule 5550(a)(2), and Nasdaq has closed the matter.